Current Context : India’s first indigenous antibiotic launched by the Ministry of Science & Technology to combat Antimicrobial Resistance (AMR).

About Nafithromycin

Created with support from BIRAC under its Biotechnology Industry Partnership Program (BIPP).

Market Name: Commercially introduced as “Miqnaf” by Wolkardt Pharma.

Purpose:

• Targets Community-Acquired Bacterial Pneumonia (CABP)caused by drug-resistant bacteria.
• Specifically benefits vulnerable populations (e.g., children and elderly).

Advantages:

• Ten times more effective than existing treatments.
• Provides faster, safer, and more tolerable results for patients.

About Antimicrobial Resistance (AMR).

• AMR occurs when microorganisms such as bacteria, viruses, fungi, and parasites evolve and become resistant to antimicrobial drugs (e.g., antibiotics, antivirals).

This reduces or nullifies the effectiveness of treatments, making infections harder to treat and increasing the risk of disease spread, severe illness, and death.